[89Zr]Zr-BI 754111
- Generic Name
- [89Zr]Zr-BI 754111
This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091
Phase 1
Terminated
- Conditions
- Carcinoma, Non-Small-Cell LungHead and Neck Neoplasms
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8
- Registration Number
- NCT03780725
- Locations
- 🇳🇱
Amsterdam UMC Locatie VUMC, Amsterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath